Paying users zone. Data is hidden behind hidden.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Microsoft Excel LibreOffice Calc

Biogen Inc. (NASDAQ:BIIB)

Common-Size Income Statement

Beginner level

Biogen Inc., common-size consolidated income statement

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Product, net
Revenues from anti-CD20 therapeutic programs
Other
Revenues
Cost of sales, excluding amortization and impairment of acquired intangible assets
Gross profit
Research and development
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration profit sharing
Loss on divestiture of Hillerød, Denmark manufacturing operations
Gain (loss) on fair value remeasurement of contingent consideration
Acquired in-process research and development
Restructuring charges
TECFIDERA litigation settlement charge
Income from operations
Interest income
Interest expense
Gain (loss) on investments, net
Foreign exchange gains (losses), net
Other, net
Other income (expense), net
Income before income tax expense and equity in loss of investee, net of tax
Income tax expense
Equity in loss of investee, net of tax
Net income
Net (income) loss attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.

Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc.’s income from operations as a percentage of revenues increased from 2017 to 2018 and from 2018 to 2019.
Income before income tax expense and equity in loss of investee, net of tax Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc.’s income before income tax expense and equity in loss of investee, net of tax as a percentage of revenues increased from 2017 to 2018 and from 2018 to 2019.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc.’s net income attributable to Biogen Inc. as a percentage of revenues increased from 2017 to 2018 and from 2018 to 2019.